相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4
Soledad A. Camolotto et al.
GUT (2021)
Hepatocyte-specific expression of human carboxylesterase 2 attenuates nonalcoholic steatohepatitis in mice
Yanyong Xu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2021)
Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway
Yiyi Zhang et al.
EXPERIMENTAL CELL RESEARCH (2020)
Complex interrelationships between nitro-alkene-dependent inhibition of soluble epoxide hydrolase, inflammation and tumor growth
Hyun-Ju Cho et al.
REDOX BIOLOGY (2020)
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer
Holly Brunton et al.
CELL REPORTS (2020)
Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer
Jody Vykoukal et al.
NATURE COMMUNICATIONS (2020)
Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer
Amarjyoti Das Mahapatra et al.
MOLECULES (2020)
The Biosynthesis of Enzymatically Oxidized Lipids
Ali A. Hajeyah et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes
Michela Capello et al.
JCO PRECISION ONCOLOGY (2020)
Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma
Qiqing Sun et al.
CANCER CELL INTERNATIONAL (2019)
Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits
Pitchai Balakumar et al.
PHARMACOLOGICAL RESEARCH (2019)
JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance
Tianyi Wang et al.
CELL METABOLISM (2018)
Anticancer Properties of Fenofibrate: A Repurposing Use
Xin Lian et al.
JOURNAL OF CANCER (2018)
Human carboxylesterases: a comprehensive review
Dandan Wang et al.
ACTA PHARMACEUTICA SINICA B (2018)
Fenofibrate and Dyslipidemia: Still a Place in Therapy?
Nicola Tarantino et al.
DRUGS (2018)
Human Carboxylesterase 2 Reverses Obesity-Induced Diacylglycerol Accumulation and Glucose Intolerance
Maxwell A. Ruby et al.
CELL REPORTS (2017)
Carboxylesterase 2 Prevents Liver Steatosis by Modulating Lipolysis, Endoplasmic Reticulum Stress, and Lipogenesis and Is Regulated by Hepatocyte Nuclear Factor 4 Alpha in Mice
Yuanyuan Li et al.
HEPATOLOGY (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
Michela Capello et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Decreased carboxylesterases expression and hydrolytic activity in type 2 diabetic mice through Akt/mTOR/HIF-1α/Stra13 pathway
Ruini Chen et al.
XENOBIOTICA (2015)
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
Michela Capello et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Cooperativity of Oncogenic K-Ras and Downregulated p16/INK4A in Human Pancreatic Tumorigenesis (Publication with Expression of Concern. See vol. 14, 2019)
Zhe Chang et al.
PLOS ONE (2014)
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis
Guodong Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study
R. P. Jones et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells
Susan E. Pratt et al.
CLINICAL CANCER RESEARCH (2013)
Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents
Chad Walesky et al.
HEPATOLOGY (2013)
Clinical implications of CES2 RNA expression in neuroblastoma
Keiichi Uchida et al.
JOURNAL OF PEDIATRIC SURGERY (2013)
The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study
A. C. Frazier-Wood et al.
PHARMACOGENOMICS JOURNAL (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
An iPSC Line from Human Pancreatic Ductal Adenocarcinoma Undergoes Early to Invasive Stages of Pancreatic Cancer Progression
Jungsun Kim et al.
CELL REPORTS (2013)
The Transcription Factor Encyclopedia
Dimas Yusuf et al.
GENOME BIOLOGY (2012)
Hepatocyte Nuclear Factor (HNF) 4α Expression Distinguishes Ampullary Cancer Subtypes and Prognosis After Resection
Florian Ehehalt et al.
ANNALS OF SURGERY (2011)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
In Vitro Evaluation of Inhibitory Effects of Antidiabetic and Antihyperlipidemic Drugs on Human Carboxylesterase Activities
Tatsuki Fukami et al.
DRUG METABOLISM AND DISPOSITION (2010)
Coactivators in PPAR-Regulated Gene Expression
Navin Viswakarma et al.
PPAR RESEARCH (2010)
Identification of an Endogenous Ligand Bound to a Native Orphan Nuclear Receptor
Xiaohui Yuan et al.
PLOS ONE (2009)
Downregulated P1 promoter-driven hepatocyte nuclear factor-4α expression in human colorectal carcinoma is a new prognostic factor against liver metastasis
Tomoko Oshima et al.
PATHOLOGY INTERNATIONAL (2007)
Hepatocyte nuclear factor 4α orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver
Michele A. Battle et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4α in the pathogenesis of human cancer
T Tanaka et al.
JOURNAL OF PATHOLOGY (2006)
Human carboxylesterase isozymes: Catalytic properties and rational drug design
Teruko Imai
DRUG METABOLISM AND PHARMACOKINETICS (2006)
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients
E Cecchin et al.
CLINICAL CANCER RESEARCH (2005)
Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3
SP Sanghani et al.
DRUG METABOLISM AND DISPOSITION (2004)
分享论文
